157 related articles for article (PubMed ID: 35713976)
1. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Yuan T; Zhou T; Qian M; Du J; Liu Y; Wang J; Li Y; Fan G; Yan F; Dai X; Li X; Wu Y; Dong X; He Q; Zhu H; Yang B
Hepatology; 2023 Jul; 78(1):103-119. PubMed ID: 35713976
[TBL] [Abstract][Full Text] [Related]
2. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.
Zhu H; Yan F; Yuan T; Qian M; Zhou T; Dai X; Cao J; Ying M; Dong X; He Q; Yang B
Cancer Res; 2020 Jun; 80(11):2204-2216. PubMed ID: 32217697
[TBL] [Abstract][Full Text] [Related]
3. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
[TBL] [Abstract][Full Text] [Related]
4. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
5. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
6. The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
Zheng L; Du J; Ge F; Qian M; Yang B; He Q; Weng Q; Zhu H
Pharmazie; 2021 Oct; 76(10):511-514. PubMed ID: 34620281
[TBL] [Abstract][Full Text] [Related]
7. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
8. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
9. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
[TBL] [Abstract][Full Text] [Related]
10. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
11. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
[TBL] [Abstract][Full Text] [Related]
12. SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.
Weiler SME; Bissinger M; Rose F; von Bubnoff F; Lutz T; Ori A; Schirmacher P; Breuhahn K
Cancer Lett; 2024 Mar; 584():216637. PubMed ID: 38242197
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod exerts
Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
[TBL] [Abstract][Full Text] [Related]
15. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
16. SDHC-related deficiency of SDH complex activity promotes growth and metastasis of hepatocellular carcinoma via ROS/NFκB signaling.
Li J; Liang N; Long X; Zhao J; Yang J; Du X; Yang T; Yuan P; Huang X; Zhang J; He X; Xing J
Cancer Lett; 2019 Oct; 461():44-55. PubMed ID: 31278950
[TBL] [Abstract][Full Text] [Related]
17. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
18. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
19. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
20. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.
Liu D; Li Q; Zang Y; Li X; Li Z; Zhang P; Feng C; Yang P; Cui J; Sun Y; Wei T; Su P; Zhao X; Yang H; Ding Y
Cell Death Dis; 2023 Apr; 14(4):264. PubMed ID: 37041150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
